COVAXIN found SAFE in Phase 1 Trial; Phase 2 Trials in September

538

TNI Bureau:  India’s first indigenous Covid-19 Vaccine, “COVAXIN” – developed by Bharat Biotech-ICMR, has been found to be safe without any adverse impacts in the Phase 1 trial.

Phase 2 trials will begin in September. If all trials succeed, the Covid Vaccine will be available in the first half of 2021, it’s believed.

Support Independent Journalism? Keep us live.

The phase 1 trial involves 375 volunteers and is being conducted at 12 sites across the country. It is expected to be completed by the end of August.

Currently, 3 Covid Vaccine trials are underway in India in different phases. They include Bharat Biotech-ICMR’s COVAXIN, Zydus Cadila’s ZyCoV-D, and the Oxford/AstraZeneca’s ChAdOx1 nCoV-19 (known as Covishield in India). Covishield is being tested and manufactured by the Pune-based Serum Institute of India (SII).

Serum Institute’s Covishield Covid Vaccine may be available earlier than the other two.

Comments are closed.